Literature DB >> 35195831

Prediction of the Ki-67 expression level and prognosis of gastrointestinal stromal tumors based on CT radiomics nomogram.

Qiuxia Feng1, Bo Tang1, Yudong Zhang1, Xisheng Liu2.   

Abstract

PURPOSE: To build and validate a radiomics nomogram integrated with the radiomics signature and subjective CT characteristics to predict the Ki-67 expression level of gastrointestinal stromal tumors (GISTs). Moreover, the purpose was to compare the performance of pathological Ki-67 expression level with predicted Ki-67 expression level in estimating the prognosis of GISTs patients.
METHODS: According to pathological results, patients were classified into high-Ki-67 labeling index group (Ki-67 LI ≥ 5%) and low-Ki-67 LI group (Ki-67 LI < 5%). Radiomics features extracted from contrast-enhanced CT(CECT) images were selected and classified to build a radiomics signature. A combined model was built by incorporating radiomics signature and determinant subjective CT characteristics using multivariate logistic regression analysis. The diagnostic performance of the radiomics signature, subjective CT model and combined model were explored by receiver operating characteristic (ROC) curve analysis and Delong test. The model with best diagnostic performance was then set up for the prediction nomogram. Recurrence-free survival (RFS) rates were compared utilizing Kaplan-Meier curve.
RESULTS: The generated combined model yielded the best diagnostic performance with area under the curve (AUC) values of 0.738 [95% confidence interval (CI): 0.669-0.807] and 0.772 (95% CI 0.683-0.860) in the training set and testing set respectively. The nomogram based on the combined model demonstrated good calibration in the training set and testing set (both P > 0.05). Patients of high-Ki-67 LI group predicted by our nomogram had a poorer RFS than patients of low-Ki-67 LI group (P < 0.0001).
CONCLUSION: This radiomics nomogram based on CECT had a satisfactory performance in predicting both the Ki-67 expression level and prognosis noninvasively in patients with GISTs, which may serve as an effective imaging tool that can assist in guiding personalized clinical treatment.
© 2022. CARS.

Entities:  

Keywords:  CT; Gastrointestinal stromal tumor; Ki-67; Radiomics

Mesh:

Substances:

Year:  2022        PMID: 35195831     DOI: 10.1007/s11548-022-02575-6

Source DB:  PubMed          Journal:  Int J Comput Assist Radiol Surg        ISSN: 1861-6410            Impact factor:   2.924


  26 in total

Review 1.  Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients.

Authors:  Fausto Petrelli; G Viale; M Cabiddu; S Barni
Journal:  Breast Cancer Res Treat       Date:  2015-09-04       Impact factor: 4.872

2.  PBK/TOPK expression in non-small-cell lung cancer: its correlation and prognostic significance with Ki67 and p53 expression.

Authors:  Bin Lei; Shuguang Liu; Wenjuan Qi; Yunfei Zhao; Yumei Li; Ni Lin; Xiaoyan Xu; Chen Zhi; Juanjuan Mei; Zhimin Yan; Liyan Wan; Hong Shen
Journal:  Histopathology       Date:  2013-09-11       Impact factor: 5.087

3.  Ki-67 labeling index may be a promising indicator to identify "very high-risk" gastrointestinal stromal tumor: a multicenter retrospective study of 1022 patients.

Authors:  Xuechao Liu; Haibo Qiu; Peng Zhang; Xingyu Feng; Tao Chen; Yong Li; Kaixiong Tao; Guoxin Li; Xiaowei Sun; Zhiwei Zhou
Journal:  Hum Pathol       Date:  2017-09-27       Impact factor: 3.466

Review 4.  Gastrointestinal stromal tumour.

Authors:  Heikki Joensuu; Peter Hohenberger; Christopher L Corless
Journal:  Lancet       Date:  2013-04-24       Impact factor: 79.321

5.  Role of Ki-67 as a prognostic factor in gastrointestinal stromal tumors.

Authors:  Borislav Belev; Iva Brčić; Juraj Prejac; Zrna Antunac Golubić; Damir Vrbanec; Jadranka Božikov; Ivan Alerić; Marko Boban; Jasminka Jakić Razumović
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

Review 6.  The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.

Authors:  Toshirou Nishida; Jean-Yves Blay; Seiichi Hirota; Yuko Kitagawa; Yoon-Koo Kang
Journal:  Gastric Cancer       Date:  2015-08-15       Impact factor: 7.370

7.  Characterizing gastrointestinal stromal tumors and evaluating neoadjuvant imatinib by sequencing of endoscopic ultrasound-biopsies.

Authors:  Per Hedenström; Bengt Nilsson; Akif Demir; Carola Andersson; Fredrik Enlund; Ola Nilsson; Riadh Sadik
Journal:  World J Gastroenterol       Date:  2017-08-28       Impact factor: 5.742

8.  A correlation research of Ki67 index, CT features, and risk stratification in gastrointestinal stromal tumor.

Authors:  Huali Li; Gang Ren; Rong Cai; Jian Chen; Xiangru Wu; Jianxi Zhao
Journal:  Cancer Med       Date:  2018-08-19       Impact factor: 4.452

Review 9.  Optimizing surgical and imatinib therapy for the treatment of gastrointestinal stromal tumors.

Authors:  Jason K Sicklick; Nicole E Lopez
Journal:  J Gastrointest Surg       Date:  2013-06-18       Impact factor: 3.452

10.  Marker of proliferation Ki-67 expression is associated with transforming growth factor beta 1 and can predict the prognosis of patients with hepatic B virus-related hepatocellular carcinoma.

Authors:  Chengkun Yang; Hao Su; Xiwen Liao; Chuangye Han; Tingdong Yu; Guangzhi Zhu; Xiangkun Wang; Cheryl Ann Winkler; Stephen J O'Brien; Tao Peng
Journal:  Cancer Manag Res       Date:  2018-04-10       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.